Cargando…

Pharmaceutical Strategy for Europe: Reflections on Public Health-Driven Drug Development, Regulation, and Policies

Detalles Bibliográficos
Autores principales:	Garattini, Silvio, Natsis, Yannis, Banzi, Rita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8115909/ https://www.ncbi.nlm.nih.gov/pubmed/33995113 http://dx.doi.org/10.3389/fphar.2021.685604

Ejemplares similares

Switching Among Biosimilars: A Review of Clinical Evidence
por: Allocati, Eleonora, et al.
Publicado: (2022)

The New and Old Europe: East-West Split in Pharmaceutical Spending
por: Jakovljevic, Mihajlo, et al.
Publicado: (2016)

Managed Entry Agreements for Pharmaceuticals in the Context of Adaptive Pathways in Europe
por: Bouvy, Jacoline C., et al.
Publicado: (2018)

Editorial: Pharmaceutical policy, impact and health outcomes
por: Kwon, Hye-Young, et al.
Publicado: (2023)

Pharmaceutical Patents in Europe: Radical Reforms Rather Than Getting Rid?
por: Garattini, Livio, et al.
Publicado: (2021)

Performance of a pharmaceutical services regionalization strategy policy in Minas Gerais, Brazil: Pre-post analysis from ERAF project
por: Luz, Tatiana Chama Borges, et al.
Publicado: (2022)

Policies to Enhance Prescribing Efficiency in Europe: Findings and Future Implications
por: Godman, Brian, et al.
Publicado: (2011)

Patient Organizations’ Funding from Pharmaceutical Companies: Is Disclosure Clear, Complete and Accessible to the Public? An Italian Survey
por: Colombo, Cinzia, et al.
Publicado: (2012)

Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications
por: Salek, Sam M., et al.
Publicado: (2019)

Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure
por: Vogler, Sabine, et al.
Publicado: (2021)

Public Policy and Pharmaceutical Innovation
por: Grabowski, Henry G.
Publicado: (1982)

Physiological and Pharmaceutical Considerations for Rectal Drug Formulations
por: Hua, Susan
Publicado: (2019)

Orphan Drugs, Compounded Medication and Pharmaceutical Commons
por: Hendrickx, Kim, et al.
Publicado: (2021)

Editorial: Shaping with data: Using pharmacoepidemiology to shape pharmaceutical policy and clinical decision-making
por: Tadrous, Mina, et al.
Publicado: (2022)

Core competencies for pharmaceutical physicians and drug development scientists
por: Silva, Honorio, et al.
Publicado: (2013)

An Overview of the Evidence and Mechanism of Drug–Herb Interactions Between Propolis and Pharmaceutical Drugs
por: Hossain, Sanowar, et al.
Publicado: (2022)

Corrigendum: Core competencies for pharmaceutical physicians and drug development scientists
por: Silva, Honorio, et al.
Publicado: (2015)

Does China’s centralized volume-based drug procurement policy facilitate the transition from imitation to innovation for listed pharmaceutical companies? Empirical tests based on double difference model
por: Gu, Yang, et al.
Publicado: (2023)

Pricing vaccines and drugs in Europe: worth differentiating?
por: Garattini, Livio, et al.
Publicado: (2020)

Future implications of ChatGPT in pharmaceutical industry: drug discovery and development
por: Zhao, Ailin, et al.
Publicado: (2023)

The Expiry of Humira(®) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
por: Moorkens, Evelien, et al.
Publicado: (2021)

Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures
por: Apolone, G, et al.
Publicado: (2005)

Changing Characteristics of Pharmaceutical Prices in China Under Centralized Procurement Policy: A Multi-Intervention Interrupted Time Series
por: Long, Hongfei, et al.
Publicado: (2022)

Strategies Implemented by Public Institutions to Approach the Judicialization of Health Care in Brazil: A Systematic Scoping Review
por: Yamauti, Sueli Miyuki, et al.
Publicado: (2020)

The change of drug utilization in China’s public healthcare institutions under the “4 + 7” centralized drug procurement policy: Evidence from a natural experiment in China
por: Lu, Jiancheng, et al.
Publicado: (2022)

The impact of key monitoring policy on the usage of policy-related drugs in Hubei Province, China
por: Wen, Xiaotong, et al.
Publicado: (2023)

Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review
por: Kawalec, Paweł, et al.
Publicado: (2017)

Editorial: The practical implication of clinical pharmacokinetics in drug development, pharmaceutical analysis, and clinical research
por: Khan, Abad, et al.
Publicado: (2023)

Effects of Volume-Price Contracts on Pharmaceutical Prices: A Retrospective Comparative Study of Public Hospitals in Hubei of China
por: Li, Zhuoxian, et al.
Publicado: (2021)

Editorial: Women in drugs outcomes research and policies: 2021
por: Alves da Costa, Filipa, et al.
Publicado: (2022)

Editorial: Pharmaceutical Innovation After World War II: From Rational Drug Discovery to Biopharmaceuticals
por: Zarros, Apostolos, et al.
Publicado: (2019)

Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications
por: Godman, Brian, et al.
Publicado: (2014)

Formulary Management Activities and Practice Implications Among Public Sector Hospital Pharmaceutical and Therapeutics Committees in a South African Province
por: Matlala, Moliehi, et al.
Publicado: (2020)

Advances in Oral Drug Delivery for Regional Targeting in the Gastrointestinal Tract - Influence of Physiological, Pathophysiological and Pharmaceutical Factors
por: Hua, Susan
Publicado: (2020)

Editorial: Rising stars in drugs outcomes research and policies: 2021
por: Lins, Robert L., et al.
Publicado: (2022)

Editorial: Metabolomics as a tool in ethnobotany-driven drug discoveries
por: Makunga, Nokwanda, et al.
Publicado: (2022)

Surface plasmon resonance unveils important pitfalls of enzyme-linked immunoassay for the detection of anti-infliximab antibodies in patients’ sera
por: Beeg, Marten, et al.
Publicado: (2021)

Pharmaceutical Chaperones and Proteostasis Regulators in the Therapy of Lysosomal Storage Disorders: Current Perspective and Future Promises
por: Mohamed, Fedah E., et al.
Publicado: (2017)

Toward an Improved Multi-Criteria Drug Harm Assessment Process and Evidence-Based Drug Policies
por: Dubljević, Veljko
Publicado: (2018)

Editorial: Opioids in the time of the COVID-19 pandemic: from cellular mechanisms to public health policy
por: John, Scott, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_egmrjio29aean32aubk8jshgak